VJOncology is committed to improving our service to you

ASCO 2020 | Toripalimab + axitinib in patients with metastatic mucosal melanoma

VJOncology is committed to improving our service to you

Sunandana Chandra

Sunandana Chandra, MD, MS, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, discusses a Phase Ib combination study of toripalimab, a humanized IgG4 mAb against PD-1 with axitinib in patients with mucosal melanoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter